title: Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
abstract: Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.
authors.affiliation: Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Cortes
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
authors.forename: Razelle
authors.initials: R
authors.lastname: Kurzrock
mesh_terms: D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D051231:Farnesyltranstransferase; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase